Tazemetostat in Relapsed/Refractory Follicular Lymphoma: A Propensity Score–Matched Analysis of E7438-G000-101 Trial Outcomes

home / between-the-lines / tazemetostat-in-rrfl-a-propensity-score-matched-analysis-of-e7438-g000-101-trial-outcomes

Expert hematologist-oncologists share insight on the E7438-G000-101 clinical trial and consider use of tazemetostat, an EZH2 inhibitor, in relapsed/refractory follicular lymphoma.

EP. 1: Relapsed/Refractory Follicular Lymphoma Overview and Treatment Options

Bruce D. Cheson, MD;Steven Park, MD

September 22nd 2022

Opening their discussion on relapsed/refractory follicular lymphoma (R/R FL), expert participants review the spectrum of available treatments in this setting.

EP. 2: Tazemetostat in R/R FL: Original Trial Data and a Propensity Score-Matched Analysis

Bruce D. Cheson, MD;Steven Park, MD

September 29th 2022

Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.

EP. 3: Key Takeaways: The Role of Tazemetostat in Relapsed/Refractory FL Moving Forward

Bruce D. Cheson, MD;Steven Park, MD

October 7th 2022

Closing out their review of tazemetostat in R/R FL, participants consider its practical use in practice alongside other novel treatment modalities.

EP. 4: Recap: Use of Tazemetostat in EZH2-Mutant vs Wild-Type Follicular Lymphoma

ONCOLOGY Staff

December 23rd 2022

Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.